Results for tag: "Corneal Graft Rejection Drug"

The Corneal Graft Rejection Drug market is a subset of the Optical Disorders Drugs market. It is composed of drugs used to treat corneal graft rejection, a condition in which the body rejects a corneal transplant. These drugs are used to reduce inflammation and prevent further damage to the cornea. Commonly used drugs include corticosteroids, cyclosporine, and tacrolimus. These drugs are typically administered topically or systemically, depending on the severity of the condition. The Corneal Graft Rejection Drug market is highly competitive, with many companies offering a variety of drugs. Some of the major players in the market include Allergan, Bausch + Lomb, Santen Pharmaceuticals, and Sun Pharmaceuticals. Other companies in the market include Akorn, Alcon, Merck, and Pfizer. Show Less Read more